USPH

U.S. Physical Therapy, Inc. (USPH) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. U.S. Physical Therapy, Inc. operates through two reportable segments: Physical Therapy Operations (outpatient clinics, home care) and Industrial Injury Prevention (IIP) services. As of June 30, 2026, the Company owned or managed 781 locations, an increase from 766 locations in the prior year. The Company is a large accelerated filer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 8.5% in Q2 and 8.2% YTD, driven by a 5.5% increase in patient visits and new hospital affiliation revenue ($5.6 million in Q2). The IIP segment revenue grew 9.1% in Q2.
• Profitability Decline: Net income attributable to shareholders decreased 20.1% in Q2 and 33.0% YTD. This decline is primarily due to a $3.0 million loss on the change in fair value of contingent earn-out consideration (compared to a $5.6 million gain in the prior year) and increased operating costs.
• Margin Compression: Gross profit margin decreased to 19.6% in Q2 from 21.1% in the prior year, attributed to unfavorable health benefit costs and increased salaries as a percentage of revenue (57.9% vs 56.6%).
• Debt Restructuring: In April 2026, the Company entered a new $450 million credit facility ($275M revolver, $175M term loan), refinancing prior debt. Total debt outstanding increased to $221.0 million.
• Acquisitions: The Company completed two major acquisitions in Q1 2026 (an 8-clinic practice and an IIP business) and one in July 2026 (12-clinic practice), contributing to clinic count growth.

Guidance, Outlook, and Risks

• Capital Allocation: The Company repurchased 306,256 shares for $19.2 million in Q2, nearly exhausting its $25.0 million authorization. A quarterly dividend of $0.46 per share was declared for September 2026.
• Non-GAAP Measures: Management highlights Adjusted EBITDA of $27.0 million (Q2) and Operating Results of $11.3 million (Q2) to exclude volatile items like earn-out revaluations and acquisition costs.
• Key Risks:
  • Reimbursement: Exposure to Medicare and third-party payor rate changes; 2026 Medicare rates increased by 1.75%.
  • Contingent Liabilities: Significant exposure to fair value adjustments on contingent earn-outs and put-right liabilities (e.g., a $54.1 million potential obligation for an IIP business stake).
  • Regulatory: Ongoing audits and potential False Claims Act litigation.
  • Integration: Costs associated with new financial/HR system implementation expected to continue through 2026.

Investor Verification Checklist

• Earn-Out Volatility: Verify the specific performance metrics driving the $3.0 million loss on contingent consideration and the likelihood of future adjustments.
• Debt Covenants: Confirm compliance with the new Credit Agreement's Consolidated Leverage Ratio and Fixed Charge Coverage Ratio covenants.
• Redeemable Non-Controlling Interest: Review the $317.5 million balance of temporary equity and the specific "put right" triggers that could force future cash outflows.
• Margin Trends: Monitor the "salaries and related costs as a percentage of revenue" metric, which rose to 58.9% YTD, to assess if cost inflation is outpacing revenue growth.
• Acquisition Integration: Assess the financial impact of the new ERP/HR system implementation costs on future operating expenses.